HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Maximilian J Hochmair Selected Research

Crizotinib

12/2022Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.
12/2021Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
11/2020Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
1/2020Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.
11/2018Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
10/2018Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
8/2017Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Maximilian J Hochmair Research Topics

Disease

31Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
05/2024 - 08/2017
14Neoplasms (Cancer)
02/2024 - 11/2017
10Brain Neoplasms (Brain Tumor)
06/2022 - 08/2017
8Disease Progression
02/2024 - 08/2017
7Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2024 - 12/2018
7Lung Neoplasms (Lung Cancer)
04/2023 - 01/2017
3Neoplasm Metastasis (Metastasis)
02/2022 - 01/2017
2Adenocarcinoma of Lung
01/2021 - 01/2019
2Dyspnea (Shortness of Breath)
11/2020 - 11/2017
2Chest Pain (Chest Pains)
11/2020 - 01/2020
2Cough
11/2020 - 01/2020
1Circulating Neoplastic Cells
02/2024
1Pleural Effusion (Pleural Effusions)
01/2024
1Hypertension (High Blood Pressure)
04/2022
1Malignant Mesothelioma
04/2022
1Sarcopenia
02/2022
1Edema (Dropsy)
01/2022
1Febrile Neutropenia
01/2021
1Pneumonia (Pneumonitis)
01/2021
1Pulmonary Embolism
01/2021
1Dehydration (Water Stress)
01/2021
1Respiratory Insufficiency (Respiratory Failure)
01/2021
1Sudden Death
01/2021
1Thrombocytopenia (Thrombopenia)
01/2021
1Hepatitis
01/2021
1Interstitial Lung Diseases (Interstitial Lung Disease)
01/2021
1Heart Arrest (Cardiac Arrest)
01/2021
1Sepsis (Septicemia)
01/2021
1Multiple Organ Failure (MODS)
01/2021
1Pancytopenia
01/2021
1Enterocolitis
01/2021
1Neutropenia
01/2021
1Fatigue
11/2020
1Weight Loss (Weight Reduction)
11/2017
1Clinical Deterioration
11/2017
1Adenocarcinoma
11/2017

Drug/Important Bio-Agent (IBA)

11PlatinumIBA
02/2024 - 05/2018
11osimertinibIBA
01/2022 - 01/2018
10Tyrosine Kinase InhibitorsIBA
04/2024 - 01/2017
9brigatinibIBA
12/2022 - 08/2017
7Etoposide (VP 16)FDA LinkGeneric
12/2023 - 12/2018
7CrizotinibIBA
12/2022 - 08/2017
7ErbB Receptors (EGF Receptor)IBA
01/2022 - 01/2019
7AfatinibIBA
01/2022 - 11/2018
6durvalumabIBA
02/2024 - 11/2019
6Anaplastic Lymphoma KinaseIBA
12/2022 - 08/2017
5Carboplatin (JM8)FDA LinkGeneric
12/2023 - 12/2018
5pembrolizumabIBA
10/2023 - 11/2017
4Biomarkers (Surrogate Marker)IBA
03/2024 - 02/2022
3DNA (Deoxyribonucleic Acid)IBA
05/2024 - 01/2018
3Pemetrexed (MTA)FDA Link
10/2023 - 01/2020
3Cisplatin (Platino)FDA LinkGeneric
10/2023 - 11/2020
3B7-H1 AntigenIBA
10/2020 - 05/2018
2atezolizumabIBA
12/2023 - 12/2018
2tremelimumabIBA
10/2023 - 01/2021
2Circulating Tumor DNAIBA
01/2021 - 01/2021
2lorlatinibIBA
11/2020 - 01/2017
1mobocertinibIBA
04/2024
1CytokinesIBA
01/2024
1Immune Checkpoint InhibitorsIBA
04/2023
1AsbestosIBA
04/2022
1capmatinibIBA
01/2022
1EnzymesIBA
01/2022
1CreatinineIBA
01/2022
1Cell-Free Nucleic AcidsIBA
01/2019

Therapy/Procedure

15Therapeutics
03/2024 - 01/2017
6Immunotherapy
03/2024 - 11/2017
6Drug Therapy (Chemotherapy)
04/2023 - 08/2017
3Time-to-Treatment
01/2022 - 09/2019
2Radiotherapy
06/2022 - 10/2018
1Cranial Irradiation
06/2022
1Combined Modality Therapy
04/2022
1Duration of Therapy
05/2020